scholarly journals In vitroEvaluation of Some Different Brands of Alprazolam Tablets

2007 ◽  
Vol 4 (4) ◽  
pp. 563-573
Author(s):  
A. Ashnagar ◽  
M. Kouchak ◽  
M. Soltani ◽  
A. Salimi
Keyword(s):  
Panic Attacks ◽  
Pharmaceutical Companies ◽  
Sedative Effects ◽  
Hplc Analyses

Alprazolam belongs to a group of medicines called benzodiazepines. These medicines are thought to work by their action on brain chemicals. Alprazolam has sedative effects and is used to treat: (i) Anxiety and (ii) Panic attacks. The results obtained in this research by various HPLC analyses and other physicochemical tests have shown that alprazolam tablets manufactured by Dr. Abidi and Poursina Pharmaceutical Companies of Iran have the standard limits acceptable by the internationally well known Pharmacopoeia such as USP and can satisfy the needs of patients quite well and are quite comparable with Xanax®of USA and Apo-Alpraz®of Canada.

The Eleventh Circuit Holds that Agreements in which Pharmaceutical Companies Pay Generic Companies Not to Compete May be Valid

2004 ◽  
Vol 32 (1) ◽  
pp. 181-184
Author(s):  
Amy Garrigues
Keyword(s):  
Pharmaceutical Companies ◽  
Court Decisions ◽  
Patent Holder ◽  
Trial Court ◽  
Court Of Appeals ◽  
The Us ◽  
Antitrust Laws ◽  
Per Se ◽  
Appeals Court ◽  
Two Sides

On September 15, 2003, the US. Court of Appeals for the Eleventh Circuit held that agreements between pharmaceutical and generic companies not to compete are not per se unlawful if these agreements do not expand the existing exclusionary right of a patent. The Valley DrugCo.v.Geneva Pharmaceuticals decision emphasizes that the nature of a patent gives the patent holder exclusive rights, and if an agreement merely confirms that exclusivity, then it is not per se unlawful. With this holding, the appeals court reversed the decision of the trial court, which held that agreements under which competitors are paid to stay out of the market are per se violations of the antitrust laws. An examination of the Valley Drugtrial and appeals court decisions sheds light on the two sides of an emerging legal debate concerning the validity of pay-not-to-compete agreements, and more broadly, on the appropriate balance between the seemingly competing interests of patent and antitrust laws.

The Cognitive Approach to Panic Attacks

PsycCRITIQUES ◽  
2010 ◽  
Vol 55 (44) ◽  
Author(s):  
Erica J. Gannon
Keyword(s):  
Panic Attacks ◽  
Cognitive Approach

Screen Patients With Panic Attacks For Drinking Issues

2006 ◽  
Vol 36 (11) ◽  
pp. 33
Author(s):  
Damian McNamara
Keyword(s):  
Panic Attacks

Investigation of Iranian Artemisia annua sedative effects in mice

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
F Emadi ◽  
M Sharifzadeh ◽  
N Yassa
Keyword(s):  
Artemisia Annua ◽  
Sedative Effects

The diazepam-like sedative effects of vaporized essential oil from the Okinawan Kabuchii citrus fruit

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
Y Kobayashi ◽  
H Takemoto ◽  
Z Fu ◽  
E Shimizu ◽  
Y Kinjo
Keyword(s):  
Essential Oil ◽  
Citrus Fruit ◽  
Sedative Effects

Offer of methods for minimizing key investment risks of “R-Pharm” JSC

2020 ◽  
Vol 17 (1) ◽  
pp. 58-67
Author(s):  
N. A. Kabanova ◽  
I. K. Alekseeva
Keyword(s):  
Strategic Planning ◽  
Pharmaceutical Company ◽  
Simulation Modeling ◽  
Return On Investment ◽  
System Analysis ◽  
Social Orientation ◽  
Pharmaceutical Companies ◽  
The Subject ◽  
High Degree

The article is devoted to the assessment of potential investment risks of the pharmaceutical company “R-Pharm” JSC with the aim of identifying the highest priority risks and developing methods for minimizing them. The relevance of the study is determined by the fact that the pharmaceutical business is characterized by a high degree of social orientation and annually invests $ 140 billion in the development of production and research, which determines the need for a risk-based approach to ensure the return on investment. The subject of this article is the investment risks of pharmaceutical companies, and the subject of research is the domestic pharmaceutical company “R-Pharm”. In order to assess the potential investment risks of “R-Pharm” JSC, the authors used elements of simulation modeling and system analysis. The proposed methods to minimize key investment risks are aimed at improving the efficiency of investment activities and is recommended as an element of the strategic planning of the company.

Sign in / Sign up

Export Citation Format

Share Document